- Home
- GROY vs PROK Comparison
GROY vs PROK Comparison
Compare GROY & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GROY
- PROK
- Stock Information
- Founded
- GROY 2020
- PROK 2015
- Country
- GROY Canada
- PROK United States
- Employees
- GROY N/A
- PROK N/A
- Industry
- GROY
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GROY
- PROK Health Care
- Exchange
- GROY Nasdaq
- PROK Nasdaq
- Market Cap
- GROY 206.6M
- PROK 212.4M
- IPO Year
- GROY 2021
- PROK N/A
- Fundamental
- Price
- GROY $1.23
- PROK $1.69
- Analyst Decision
- GROY Strong Buy
- PROK Buy
- Analyst Count
- GROY 4
- PROK 5
- Target Price
- GROY $3.25
- PROK $4.50
- AVG Volume (30 Days)
- GROY 746.6K
- PROK 537.9K
- Earning Date
- GROY 11-04-2024
- PROK 11-12-2024
- Dividend Yield
- GROY N/A
- PROK N/A
- EPS Growth
- GROY N/A
- PROK N/A
- EPS
- GROY N/A
- PROK N/A
- Revenue
- GROY $7,764,000.00
- PROK N/A
- Revenue This Year
- GROY $282.38
- PROK N/A
- Revenue Next Year
- GROY $110.13
- PROK N/A
- P/E Ratio
- GROY N/A
- PROK N/A
- Revenue Growth
- GROY 197.02
- PROK N/A
- 52 Week Low
- GROY $1.16
- PROK $1.18
- 52 Week High
- GROY $2.21
- PROK $4.44
- Technical
- Relative Strength Index (RSI)
- GROY 49.41
- PROK 53.24
- Support Level
- GROY $1.20
- PROK $1.50
- Resistance Level
- GROY $1.25
- PROK $1.82
- Average True Range (ATR)
- GROY 0.04
- PROK 0.14
- MACD
- GROY 0.00
- PROK 0.01
- Stochastic Oscillator
- GROY 50.51
- PROK 76.14
About GROY Gold Royalty Corp.
Gold Royalty Corp is a precious metals-focused royalty and streaming company. It offers creative financing solutions to the metals and mining industry. The company's mission is to acquire royalties, streams and similar interests at varying stages of the mine life cycle to build a balanced portfolio offering near, medium and longer-term attractive returns for investors. It has its business as a single operating segment, being the investment in royalty and mineral stream interests.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.